Immunotherapy Benefits Select Patients With Late-Stage NSCLC
A systematic review revealed characteristics that may help clinicians predict which patients will benefit from immunotherapy.
Related Articles
Gene Expression Score May Guide Treatment in Uveal Melanoma
A gene expression score may be able to predict outcomes of adoptive cell therapy and prevent unnecessary surgeries in patients with uveal melanoma, researchers say.
MRI-Guided Neoadjuvant Chemo May Benefit Patients With HR-, HER2+ Breast Cancer
Early data suggest that using MRI to guide neoadjuvant chemotherapy may be beneficial for patients with stage II-III, HR-, HER2+ breast cancer.
Cancer Survivors Have Higher Risk of Functional Disability
US cancer survivors are more likely than the general population to have a mobility or self-care disability, a large study suggests.
Corrections, Retractions Issued for Papers by Dana-Farber Researchers
Several corrections and retractions have been issued for study reports written by researchers at the Dana-Farber Cancer Institute since errors in these and other papers…
Trastuzumab Deruxtecan May Fulfill Unmet Need in HER2-Overexpressing NSCLC
Trastuzumab deruxtecan demonstrated activity in a phase 2 trial of patients with HER2-overexpressing, relapsed/refractory, unresectable and/or metastatic NSCLC.
American Association for Cancer Research Annual Meeting Archives
Close more info about Alectinib Deemed “Highly Promising” for Pediatric ALK Fusion-Positive Cancers Close more info about Alectinib Deemed “Highly Promising” for Pediatric ALK Fusion-Positive
Does Fracking Cause Cancer?
There are only a few studies investigating whether fracking may cause cancer, so more research is needed to draw a definitive conclusion, said Nicole Deziel,…
Saruparib Appears Safe, Active in Advanced Breast Cancer
Saruparib may be safe and effective for patients with homologous recombination repair-deficient, HER2-negative breast cancer.
Alectinib Deemed “Highly Promising” for Pediatric ALK Fusion-Positive Cancers
Alectinib has demonstrated activity in children with ALK fusion-positive cancers in a phase 1/2 trial.
Olaparib Disappoints as Maintenance in Metastatic NSCLC
Adding olaparib to pembrolizumab maintenance did not improve outcomes in patients with metastatic squamous NSCLC in a phase 3 trial.